Form 8-K - Current report:
SEC Accession No. 0001104659-24-121582
Filing Date
2024-11-21
Accepted
2024-11-21 16:43:20
Documents
16
Period of Report
2024-11-21
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2428677d2_8k.htm   iXBRL 8-K 51509
2 EXHIBIT 4.1 tm2428677d2_ex4-1.htm EX-4.1 69182
3 EXHIBIT 4.2 tm2428677d2_ex4-2.htm EX-4.2 252599
4 EXHIBIT 10.1 tm2428677d2_ex10-1.htm EX-10.1 1107774
  Complete submission text file 0001104659-24-121582.txt   1937669

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA btai-20241121.xsd EX-101.SCH 3048
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE btai-20241121_lab.xml EX-101.LAB 34240
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE btai-20241121_pre.xml EX-101.PRE 22381
18 EXTRACTED XBRL INSTANCE DOCUMENT tm2428677d2_8k_htm.xml XML 3562
Mailing Address 555 LONG WHARF DRIVE NEW HAVEN CT 06511
Business Address 555 LONG WHARF DRIVE NEW HAVEN CT 06511 203-643-8060
BioXcel Therapeutics, Inc. (Filer) CIK: 0001720893 (see all company filings)

EIN.: 821386754 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38410 | Film No.: 241485086
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)